---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091671"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2026-08-06T12:05:35+00:00"
generated_at: "2026-08-06T12:10:21.498931+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q2 net loss $57.3M; completes sevasemten sale to Servier for up to $2.65B

## Summary
- Net loss $57.3M ($0.53/share) vs $36.1M ($0.34) in Q2 2025; R&D $47.5M, G&A $14.4M.
- Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront + up to $1.1B milestones (closed July 2026).
- Cash $460.7M at June 30; pro forma $2.01B after sale proceeds (pre-tax/transaction costs).
- Positive top-line Phase 2 CIRRUS-HCM data for EDG-7500 in HCM; Phase 3 expected Q4 2026.
- EDG-15400 Phase 1 completed; Phase 2 in HFpEF expected H2 2026.

## SEC filing metadata
- accession: 0001104659-26-091671
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2026-08-06T12:05:35+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/0001104659-26-091671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/tm2621653d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091671
- JSON: https://secwatch.observer/filing/0001104659-26-091671.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.